Last reviewed · How we verify
Leuprorelin Acetate Depot 3M
Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.
Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced testosterone and estrogen production. Used for Advanced prostate cancer, Hormone receptor-positive breast cancer (premenopausal women), Endometriosis.
At a glance
| Generic name | Leuprorelin Acetate Depot 3M |
|---|---|
| Also known as | Leuprolide acetate Depot 3M |
| Sponsor | Takeda |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Leuprorelin works by binding to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect), followed by sustained suppression of these hormones through receptor desensitization. This results in castration-level testosterone suppression in males and estrogen suppression in females, making it effective for hormone-dependent conditions. The depot formulation provides sustained release over 3 months.
Approved indications
- Advanced prostate cancer
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Injection site reaction
- Decreased libido
- Erectile dysfunction
- Headache
- Fatigue
- Gynecomastia
- Bone pain (flare)
Key clinical trials
- A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty (PHASE4)
- RWE About QOL and Compliance of Patients With OFS in China
- Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer
- Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leuprorelin Acetate Depot 3M CI brief — competitive landscape report
- Leuprorelin Acetate Depot 3M updates RSS · CI watch RSS
- Takeda portfolio CI